Leerink Partnrs Comments on R1 RCM Inc.’s Q2 2024 Earnings (NASDAQ:RCM)

R1 RCM Inc. (NASDAQ:RCM) – Leerink Partnrs issued their Q2 2024 EPS estimates for shares of R1 RCM in a research report issued on Monday, April 29th. Leerink Partnrs analyst M. Cherny forecasts that the healthcare provider will post earnings of ($0.01) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for R1 RCM’s current full-year earnings is ($0.05) per share. Leerink Partnrs also issued estimates for R1 RCM’s Q3 2024 earnings at $0.03 EPS, FY2024 earnings at $0.09 EPS, FY2025 earnings at $0.24 EPS, FY2027 earnings at $0.59 EPS and FY2028 earnings at $0.84 EPS.

Several other brokerages also recently issued reports on RCM. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of R1 RCM in a research report on Wednesday, April 10th. SVB Leerink assumed coverage on R1 RCM in a research note on Monday, February 26th. They set an “outperform” rating and a $14.00 price objective for the company. Barclays reissued an “equal weight” rating and issued a $14.00 target price on shares of R1 RCM in a report on Wednesday, February 28th. Citigroup raised R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Wednesday, March 20th. Finally, Truist Financial restated a “hold” rating and issued a $16.00 price objective on shares of R1 RCM in a research report on Monday, April 1st. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, R1 RCM currently has a consensus rating of “Moderate Buy” and an average price target of $16.87.

R1 RCM Trading Up 0.6 %

Shares of NASDAQ RCM opened at $12.36 on Wednesday. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.57. The stock has a 50 day moving average of $12.89 and a two-hundred day moving average of $11.41. R1 RCM has a twelve month low of $8.87 and a twelve month high of $18.70.

Insiders Place Their Bets

In other news, President John M. Sparby sold 10,046 shares of R1 RCM stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $14.33, for a total value of $143,959.18. Following the completion of the sale, the president now owns 265,986 shares of the company’s stock, valued at $3,811,579.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 36.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On R1 RCM

Institutional investors have recently added to or reduced their stakes in the company. Voss Capital LLC raised its stake in shares of R1 RCM by 553.9% in the 4th quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock valued at $75,311,000 after acquiring an additional 6,035,340 shares during the period. Norges Bank purchased a new position in R1 RCM in the fourth quarter valued at about $42,539,000. P2 Capital Partners LLC lifted its stake in shares of R1 RCM by 70,366.3% during the fourth quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock worth $37,368,000 after purchasing an additional 3,530,277 shares in the last quarter. Sea Cliff Partners Management LP purchased a new stake in shares of R1 RCM in the fourth quarter worth about $18,459,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of R1 RCM by 81.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,826,545 shares of the healthcare provider’s stock valued at $29,879,000 after buying an additional 1,269,837 shares in the last quarter. Hedge funds and other institutional investors own 61.10% of the company’s stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.